The Business Research Company’s Dermatitis
Drugs Market covers market characteristics, size and growth,
segmentation, regional and country breakdowns, competitive landscape, market
shares, trends and strategies for this market.
The dermatitis drugs market
consists of sales of dermatitis drugs such as corticosteroids, calcineurin
inhibitors, PDE4 inhibitors which are used to cure inflammation of the outer
layer of the body, characterized by itchy rashes on swollen and reddened skin.
Some of the major dermatitis drugs include Triamcinolone, Clobetasol,
Betamethasone, Hydrocortisone, Fluocinonide and Clobex.
Major players in the market are LEO Pharma A/S, Novartis AG, Pfizer Inc.,
Regeneron Pharmaceuticals Inc. and Sanofi S.A.
Growth in Atopic Dermatitis
market is primarily driven by the increasing global prevalence of the disease.
Prevalence of dermatitis in children is estimated to be around 15-20% while it
is 1-3% in adults. The rising cases of food allergies are adding to the
prevalence of dermatitis which ultimately leads to the increase in demand for
the medicines to cure this disease. For example, a study conducted in Norway
highlights that the overall incidence rate of atopic dermatitis has increased
from 0.028 per person year in 2009 to 0.034 per person year in 2014.
The strict government regulations
are one of the restraints for the dermatitis drug market. Atopic Dermatitis
(eczema) usually occurs at a very early stage (0-5 years). In order to find the
efficacy and efficiency of drug, it has to be tried on the every type of
patients. The effects of certain drugs in adults are quite different than in
children, as a reason results of the clinical trial cannot be used for the
production of drug that will be served to the children. This hinders the
research and requires more efforts in clearing regulation set by FDA. For
example, as the patient population is largely children, FDA in its CFR Code
Title 21, Part 50 Protection of Human Subjects, and subpart D has laid down
guidelines for the additional safeguard for children in clinical investigation.
The regulation is in compliance with Children’s Health Act of 2000 that
requires all the children subjected to clinical trial be given additional
protection.
View complete Report: https://www.thebusinessresearchcompany.com/report/dermatitis-drugs-global-market-report
The Dermatitis market has
witnessed a trend of increasing Mergers and Acquisitions (M&As), done with
the purpose of business expansion and increasing visibility. M&As are
playing a significant role in today's world and are assumed to expand this market
in the years to come. The vendors in this industry are focusing on
collaboration and partnerships to expand their portfolio and improve market
presence. Companies are also strategically making M&As with a view to
reduce competition and increase the scalability of their business.
Browse Year End
Discounted Reports Offered By TBRC @ https://www.thebusinessresearchcompany.com/discounted-reports.aspx
About Us:
The Business Research Company is a Business Intelligence
Company which excels in company, market and consumer research. It has offices
in the UK, the US and India and a network of trained researchers in 15
countries globally.
Contact Information:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company
View Our Latest Press Releases: https://www.thebusinessresearchcompany.com/press-release.aspx
Comments
Post a Comment